companies / shanx-nl
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-23 json
| total_raised | 16,200,00016.2M (derived) | derived |
|---|---|---|
| founded | 2019 | |
| hq | Eindhoven, Netherlands | |
| industry | unknown | |
| stage | seed |
ShanX Medtech develops in-vitro diagnostics for ultra-fast antimicrobial susceptibility testing to fight antibiotic resistance. It serves clinicians who need to pick the right antibiotic quickly. Its FLORA chemistry reads pathogen metabolism in real time, delivering results within about an hour.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2026-03-01 | seed | 16,200,00016.2M | null | ○ |
| fact | status | src |
|---|---|---|
| Seed, $16.2M | attributed | ○ |
| total | derived: Stated total is below the largest recorded round; sum of recorded rounds used | derived |
| existence | self-reported | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-09-28provenance_total: unknown → derived, derived 2026-05-23 | provenance_total | unknown → derived | derived 2026-05-23 |
| 2026-09-28total_raised: 15000000 → 16200000, derived 2026-05-23 | total_raised | 15000000 → 16200000 | derived 2026-05-23 |
Records begin 2026-09-24. all_changes